Understanding how certain genetic changes cause nerve cell damage in ALS and frontotemporal dementia
Official title: Mechanisms of chimeric DPR production and toxicity in c9ALS/FTD
Funded at Emory University · NIH-11128738 · Data updated 2026-11-12
This study is looking into how a specific gene mutation causes harmful proteins to form in people with ALS and Frontotemporal Dementia, with the hope of finding new treatment options that could help improve their lives.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | July 1, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $629,343 |
| NIH project number | 5R01NS137434-02 |
| Project ID | NIH-11128738 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with ALS or FTD, particularly those with the C9orf72 genetic mutation.
✕Less likely to help
Patients with ALS or FTD who do not have the C9orf72 mutation may not benefit directly from this research.
What this research studies
This research investigates the genetic mechanisms behind the production of toxic proteins in patients with Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). It focuses on a specific genetic mutation in the C9orf72 gene that leads to the formation of harmful dipeptide repeat proteins. By exploring how these proteins are produced and their effects on nerve cells, the research aims to uncover potential targets for new treatments. Patients may benefit from insights that could lead to innovative therapies for these debilitating conditions.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that slow down or halt the progression of ALS and FTD.
How similar studies have gone: Previous research has shown promising results in understanding genetic mechanisms in similar neurodegenerative disorders, indicating potential for success in this area.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Mceachin, Zachary Thomas — Emory University
- Study coordinator: Mceachin, Zachary Thomas
Related research
Other NIH-funded projects on the same topics.
-
Administrative and Engagement Core for Breast Cancer Breakthrough in Kenya
A national effort in Kenya to speed up how we screen for breast cancer and connect women to treatment, using teamwork across institutions.
-
Collaborative research program to advance patient care
A multi-project research effort at Emory University aims to push forward medical knowledge that could help people with illnesses in the future.
-
Project-003: A multi-partner research program at Emory University
A multi-faceted NIH grant at Emory University aims to advance understanding in a focused area over several years to benefit patients with diseases or conditions connected to the research.
-
Project-002: advancing patient care through coordinated research at Emory
A multi-project NIH grant at Emory aims to translate findings into better care for people with a health condition by coordinating research efforts across teams.
-
Project-006: A Multidisciplinary Emory Initiative to Advance Medical Understanding
A multi-project NIH grant at Emory University aims to push forward medical knowledge in areas that could eventually help patients.
-
Project-005: A multi-component research effort at Emory University
A multi-part NIH grant from Emory University aims to advance understanding in a specific health area over several years with potential patient benefits in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.